Regularly monitor liver function tests (LFTs), including ALT, AST, and bilirubin, before starting Etabus and then at least monthly during treatment. Adjust dosage or discontinue therapy if significant abnormalities arise.
Closely observe patients for symptoms of disulfiram-alcohol reaction, such as nausea, vomiting, flushing, and palpitations. Educate patients thoroughly on the risks of alcohol consumption, including even small amounts.
Monitor for neurological symptoms, such as peripheral neuropathy or encephalopathy. These are rare but serious side effects requiring immediate medical attention and potential dosage reduction or treatment cessation.
Conduct regular patient interviews focusing on adherence to the prescribed regimen and the presence of any side effects. Encourage open communication and address any concerns promptly.
Regularly assess patient’s psychological state, as Etabus therapy can exacerbate existing psychiatric conditions. Consider psychological support if needed.
Maintain detailed records of all LFTs, adverse events, and patient interactions. This documentation is crucial for tracking treatment effectiveness and managing potential complications.
Consider using a patient diary to monitor alcohol consumption and side effects. This can enhance patient engagement and improve treatment outcomes.
Collaborate with other healthcare professionals, such as psychiatrists or counselors, if the patient requires additional support to manage their addiction or associated mental health issues.
Regularly review the patient’s response to Etabus therapy and adjust the treatment plan as needed based on individual circumstances and response to treatment. This includes potential dosage adjustments and careful consideration of alternative treatment options if necessary.
